Compounded Tirzepatide: What It Is, Legal Status, and Who Should Consider It

For much of 2023 and 2024, compounded tirzepatide was the primary route of access to tirzepatide therapy for many patients. The brand-name product — Zepbound for obesity, Mounjaro for type 2 diabetes — was in persistent shortage, prices ran $1,000+ per month without insurance, and pharmacy compounding laws created a legal window for compounded versions at a fraction of the cost.

That landscape has since shifted significantly. The FDA declared tirzepatide shortages resolved in early 2025, triggering legal battles over whether compounded versions could continue. Understanding where things stand — and what it means for your treatment options — requires knowing the regulatory framework.

What "Compounded" Actually Means

Pharmaceutical compounding is the practice of a licensed pharmacy preparing a customized medication for an individual patient. Compounding has a long history in medicine — it's how patients get medications in specific doses, forms, or combinations not available commercially. Think of a child who needs a liquid form of a drug only available as a tablet, or a patient allergic to a filler ingredient in a commercial product.

A compounded drug is not FDA-approved. It is not tested for sterility, potency, or efficacy by the FDA before dispensing (though it may be made under state pharmacy board oversight). This is distinct from a generic drug, which undergoes FDA review to confirm bioequivalence to the brand product.

For tirzepatide specifically, compounding pharmacies typically produce:

• Tirzepatide for subcutaneous injection (same administration route as Mounjaro/Zepbound)
• Sometimes at custom doses not available in commercial pens (e.g., very low starting doses for sensitive patients)
• Sometimes with added B12, L-carnitine, or other compounds — a practice without evidence basis and of uncertain safety

The FDA Shortage Window: How Compounding Became Legal

Under Section 503A and 503B of the Federal Food, Drug, and Cosmetic Actcompounding pharmacies may legally compound copies of FDA-approved drugs that appear on the FDA's Drug Shortage List. This provision exists to ensure patient access when supply of a commercially available drug is insufficient to meet demand.

Tirzepatide (both Mounjaro and Zepbound) appeared on the FDA shortage list in 2022–2024 as Eli Lilly struggled to scale manufacturing to meet explosive post-approval demand. During this window:

• Both 503A pharmacies (patient-specific compounding) and 503B outsourcing facilities (larger-scale compounding) were legally permitted to compound tirzepatide
• patients accessed compounded tirzepatide through telehealth platforms and compounding pharmacies, often at $200–$500/month vs. $1,000+ for brand
• Prescribers could legally write prescriptions for compounded tirzepatide directed to specific compounding pharmacies

In October 2024the FDA determined that tirzepatide shortages were resolvedremoving it from the Drug Shortage List. This triggered mandatory cessation timelines for compounding: 503B outsourcing facilities had until November 2024 to stop; 503A pharmacies had until March 2025 (later extended) under FDA enforcement discretion policies.

503A vs. 503B Pharmacies: Which Is Safer?

Not all compounding pharmacies operate under the same regulatory framework, and this matters for safety:

From a patient safety perspective, 503B outsourcing facilities operate under significantly stricter quality controls — they are FDA-registered, federally inspected, and required to follow current Good Manufacturing Practice (cGMP) standards similar to pharmaceutical manufacturers. A 503A pharmacy compounding injectable tirzepatide in a back room is operating under far less oversight.

The FDA has documented safety concerns with compounded injectables — including cases of incorrect potency (both under- and over-dosing), contamination, and sterility failures at unregistered compounders. Patients accessing compounded tirzepatide should confirm their pharmacy is a state-licensed, PCAB-accredited compounding pharmacy or an FDA-registered 503B outsourcing facility.

How Compounded Tirzepatide Differs from Brand Zepbound

The core active molecule — tirzepatide — is the same dual GIP/GLP-1 receptor agonist in both compounded and brand versions. However, the products differ in several important ways:

• Formulation: Zepbound is a pre-filled autoinjector pen with a specific concentration and delivery mechanism tested in clinical trials. Compounded tirzepatide is typically a vial-and-syringe formulation that patients draw and inject themselves — a slightly more complex process with more room for dosing error
• Excipients: The inactive ingredients (buffers, stabilizers, preservatives) in compounded versions may differ from the proprietary Zepbound formulation. Some compounders add ingredients (B12, carnitine) not tested for safety in this combination
• Dose delivery accuracy: Zepbound's autoinjector pens are precision-engineered for consistent dose delivery. Syringe drawing from a vial introduces more variability
• No bioequivalence demonstration: Unlike a generic drug, compounded tirzepatide has not undergone FDA testing to confirm it produces the same blood concentration profile as Zepbound. The assumption of equivalence is reasonable but not rigorously validated
• Storage and stability: Zepbound's shelf life and storage requirements are rigorously studied. Compounded formulations may have different stability profiles that aren't fully characterized

The Eli Lilly Lawsuit Context

Eli Lilly — the manufacturer of Zepbound and Mounjaro — has pursued legal action against compounding pharmacies and telehealth companies it alleges illegally continued compounding tirzepatide after the FDA shortage resolution in October 2024.

Key developments in the legal landscape:

• Lilly filed suit against numerous 503A compounders it alleged were operating after the enforcement deadline, arguing they were no longer protected by the shortage exemption
• The Alliance for Pharmacy Compounding (ACPA) filed suit against the FDA challenging the shortage resolution determination itself, arguing supply remained insufficient to meet patient demand
• In early 2025, a federal judge ruled in the FDA's favor, affirming the agency's authority to determine shortage resolution. This ruling significantly narrowed the legal window for ongoing 503A compounding
• 503B facilities faced an earlier, firmer deadline and largely ceased compounding branded tirzepatide by late 2024

As of mid-2025, the legal status of most compounded tirzepatide is uncertain to precarious for patients and prescribers outside very narrow personalization exceptions (e.g., documented allergy to a Zepbound excipient documented in the patient's medical record).

Quality Control: What to Ask Before Using Compounded Tirzepatide

For patients who are currently using compounded tirzepatide or are considering it where legally permitted, these are the questions to ask:

1. Is the pharmacy a licensed 503B outsourcing facility or an accredited 503A compounding pharmacy? Ask for their FDA registration number (503B) or PCAB accreditation certificate (503A)
2. Does the pharmacy conduct certificate of analysis (COA) testing on each lot? Request documentation confirming potency (within ±10% of labeled amount) and sterility testing
3. What is the concentration and what are all ingredients? Avoid preparations with undefined "added" ingredients without clinical justification
4. What is the beyond-use date (BUD) and how should it be stored? Most compounded injectable tirzepatide should be refrigerated and has a BUD of 30–90 days
5. How is the prescription being written? A legitimate compounded prescription includes a specific clinical rationale — not just a workaround for cost

Who's a Good Candidate: Current Practical Reality

Given the rapidly evolving legal landscape, who can legitimately access compounded tirzepatide going forward?

• Patients with documented allergy to a Zepbound-specific excipient — a genuinely narrow exception that requires documentation in medical records
• Patients requiring a non-standard dose for a specific clinical reason documented by their prescriber
• Patients in states where certain compounding exceptions persist — state law interacts with federal law in complex ways; some state pharmacy boards have challenged FDA shortage resolution findings

For most patients seeking tirzepatide therapy primarily due to cost, the practical pathways in 2025 are: Lilly's Zepbound Savings Program (monthly supply for $550 for cash-pay patients as of 2024), insurance coverage pursuit, or exploring GLP-1 programs with coverage assistance.

How Truventa Handles Prescribing

Truventa Medical physicians prescribe GLP-1 medications — including tirzepatide — within current FDA guidelines and applicable state and federal law. Our prescribing practices evolve in real time as the regulatory landscape around compounding changes. We do not prescribe compounded medications from unverified or unaccredited pharmacies, and we will not write compounding prescriptions that lack legitimate clinical justification documented in your medical record.

If you have questions about access, cost, or legal pathways to tirzepatide therapy, Our network of licensed providers can walk you through your specific options during your consultation — including assistance with prior authorization, manufacturer savings programs, and FDA-compliant alternatives.